Option Care (OPCH) Q1 2026 Earnings Transcript

Option Care Health reported Q1 revenue of $1.4 billion, up just over 1%, but revenue growth was dragged by roughly 600 bps from its CID portfolio and full-year gross profit headwind expectations increased to $55 million from $25 million-$35 million. Management cut 2026 revenue guidance to $5.675 billion-$5.775 billion while keeping EBITDA at $480 million-$505 million and adjusted EPS at $1.82-$1.92, supported by cost actions, strong acute growth in the high single digits, and $17 million of share repurchases. The company also expanded its revolver to $850 million and said it does not expect further Stelara-related headwinds in 2026 or carryover into 2027.

Analysis

The market is likely underestimating how much of this reset is a share-shift event versus a one-time profit reset. The key second-order effect is that a chunk of chronic revenue appears to have migrated toward lower-touch channels or competitors, which means OPCH’s recovery is not just a demand rebound but a reacquisition problem; that typically takes quarters, not weeks, and it likely comes with some permanent pricing/mix degradation. The fact that management kept EBITDA/EPS intact by pulling levers on variable costs and buybacks tells me the near-term P&L is being stabilized financially, not operationally.

The better read-through is to competitors with more aggressive biosimilar contracting, stronger payer relationships, or less dependence on high-touch authorization workflows. If payers are steering biosimilar utilization and self-administration more forcefully, the winners are likely to be manufacturers and alternate-site operators that can process faster and accept thinner economics; OPCH’s disclosed loss of census suggests the industry is moving from service-led differentiation toward contract-led distribution. That is a subtle but important negative for OPCH’s moated-provider narrative.

The contrarian element: the stock may not deserve a dramatic de-rate if investors believe the revenue issue is isolated to the Stelara transition and the rest of the platform is actually accelerating. Acute growth, clinic utilization, and site-of-care programs are offsetting the chronic drag, so the core earnings engine may be more resilient than the headline revenue print implies. But if the rebuild in census stalls into 2H, the market will start pricing this as a structural competition and mix problem rather than a transitory reset, which is a much lower-multiple setup.

Key Decisions for Investors

• Short OPCH on strength for 4-8 weeks into the next print if the stock rerates on the maintained EBITDA guide; thesis is that consensus will eventually re-cut the 2026-27 revenue growth path as chronic census recovery proves slower than management’s sequential framing.
• Pair trade: long stronger payer/contracting healthcare services names versus short OPCH over 3-6 months; the basket should favor operators with less exposure to high-friction reauthorization workflows and better biosimilar pass-through economics.
• If holding OPCH, hedge with out-of-the-money put spreads into the next earnings cycle; the risk is not another EBITDA miss but a second guidance reset if patient rebuild does not show up by mid-2H.
• Watch for a tactical long only if quarterly revenue inflects above the mid-single-digit sequential plan in 2Q/3Q; absent that, the stock likely stays range-bound with downside skew because EBITDA is being defended by cost cuts, not durable top-line acceleration.